戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 eive intravenous 1.26% sodium bicarbonate or intravenous 0.9% sodium chloride and 5 days of oral acet
2 and drug reactions were rare in both groups (intravenous: 0.7%, oral: 0.5%).
3 ho were scheduled for angiography to receive intravenous 1.26% sodium bicarbonate or intravenous 0.9%
4                          Patients who needed intravenous acetylcysteine treatment for paracetamol ove
5 patients with SMA1 received a single dose of intravenous adeno-associated virus serotype 9 carrying S
6                        Cangrelor is a potent intravenous adenosine diphosphate-receptor antagonist th
7 enetration of the brain parenchyma following intravenous administration in mice.
8                          In the adult mouse, intravenous administration of 1 x 10(11) vector genomes
9 analyzed ex vivo at 3, 6, 24, and 96 h after intravenous administration of 25 mug of (89)Zr-MSB001085
10 ntervention (control, CONT) as well as after intravenous administration of either propranolol (PROP),
11                                              Intravenous administration of etelcalcetide (n = 503) or
12                 If this hypothesis is valid, intravenous administration of MSCs should improve outcom
13                                              Intravenous administration of the MagMBs to mice bearing
14                             In addition, the intravenous administration of tocotrienol entrapped in t
15 occur in the body as a result of therapeutic intravenous administration, surgery, infections or decom
16 th the observed plasma clearance values upon intravenous administration.
17 ility to specifically reach tumors following intravenous administration.
18 s models and aqueous solubility suitable for intravenous administration.
19         Both conditions were performed under intravenous alcohol administration (6% vol/vol infusion
20 participants could press a button to receive intravenous alcohol using the Computerized Alcohol Infus
21 domly assigned to medical therapy (including intravenous alteplase when eligible) and neurovascular t
22 her microscopy or culture, to receive either intravenous amphotericin B deoxycholate (amphotericin) (
23 nal responses during the first 4 hours after intravenous and intragastric Pi loading in rats.
24 expression of miR-194 enhanced metastasis of intravenous and intraprostatic tumor xenografts.
25 growth in vivo during treatment through both intravenous and non-local subcutaneous injections.
26 dicitis, although existing studies comparing intravenous and oral antibiotics for this purpose are li
27 el II and III evidence supporting the use of intravenous and oral antiviral therapy for the treatment
28 es were obtained by transducing a peripheral intravenous and pulmonary artery catheter, respectively,
29         The pharmacokinetics shows that both intravenous and subcutaneous applications are viable rou
30 rotocol, and avoiding the unnecessary use of intravenous and urinary tract catheters.
31 d, including intracoronary, intramyocardial, intravenous, and epicardial.
32 e per week or mFOLFOX (oxaliplatin, 85 mg/m2 intravenous, and fluorouracil, 2400 mg/m2 intravenous in
33                                              Intravenous anesthetic propofol binds to 5-lipoxygenase
34 be directly activated and potentiated by the intravenous anesthetic propofol.
35                               Propofol is an intravenous anesthetic that produces its anesthetic effe
36                           Notably, intensive intravenous antibiotic treatment of patients with melioi
37       Compared with oral antibiotics, use of intravenous antibiotics after discharge in children with
38 ed (median: 99/hospital), and utilization of intravenous antibiotics after discharge ranged from 0% t
39 icated appendicitis who received oral versus intravenous antibiotics after discharge.
40 ur case, early recognition, culture-specific intravenous antibiotics and urgent surgical treatment co
41 re is increasing interest in using high-dose intravenous ascorbate (IVC) in treating this disease par
42 n macrophages and boosted protection against intravenous bacterial challenge.
43 taxel (175 mg/m(2) on day 1) with or without intravenous bevacizumab (15 mg/kg on day 1) in 21 day cy
44 reatment as the control group plus 7.5 mg/kg intravenous bevacizumab on day 1 of every cycle of chemo
45 cination approach, direct tumor injection or intravenous biodistribution to an orthotopic PDAC site.
46 alog whose potency and duration of action on intravenous bolus injection in diabetic rats are indisti
47 es; bortezomib (1.3 mg/m(2)) was given as an intravenous bolus or subcutaneous injection on days 1, 4
48 ndomly assigned (1:1) to ketamine (0.5 mg/kg intravenous bolus) or saline adjunctive to the anaesthet
49 ive voice and web response system to receive intravenous brentuximab vedotin 1.8 mg/kg once every 3 w
50 ely in four equal doses); after Nov 8, 2007, intravenous busulfan was given (0.8-1.2 mg/kg per dose f
51                                              Intravenous but not gastric Pi loading in parathyroidect
52 bitors, including prasugrel, ticagrelor, and intravenous cangrelor.
53 th other AMPs, in the treatment of S. aureus intravenous catheter infections.
54 multivariate regression analysis, only early intravenous catheter removal (on day 2) [odds ratio: 0.3
55 elow the knee, a single preoperative dose of intravenous cefazolin compared with saline did not reduc
56 ptibility, presence of fever, comorbidities (intravenous central lines, urinary catheters, diabetes m
57 ite of action is indicated by the ability of intravenous CGRP to trigger migraine in humans and the e
58  HI-EOL care comprised any of the following: intravenous chemotherapy < 14 days from death; more than
59 eview of Group D eyes treated initially with intravenous chemotherapy (IVC) and followed up for at le
60                                     Low-risk intravenous chemotherapy agents had overuse that continu
61  the outcomes of retinoblastoma treated with intravenous chemotherapy and IVM as salvage for vitreous
62 ous seeding from retinoblastoma treated with intravenous chemotherapy and IVM from 2012 to 2016.
63 1:1:1 (blocking used; block size of four) to intravenous chemotherapy of either cisplatin (50 mg/m(2)
64 ts, with highest rates among those receiving intravenous chemotherapy with high chemotherapy-induced
65 tomycin (one dose of 12 mg/m(2) on day 1) or intravenous cisplatin (one dose of 60 mg/m(2) on days 1
66 e-blind, counterbalanced design, CD received intravenous cocaine (30 mg/70 kg) before one session (CD
67 ked on developing a second-order schedule of intravenous cocaine reinforcement to investigate the neu
68                                              Intravenous colistin is difficult to use because plasma
69 on by computed tomography scan with oral and intravenous contrast is safe and feasible, whereas perfo
70              Purpose To assess the effect of intravenous contrast media on renal function in neonates
71 tion rate in the cohort that received 5-hour intravenous corticosteroid prophylaxis.
72 0-30) oral corticosteroids (PUCAI 35-60), or intravenous corticosteroids (PUCAI >/=65).
73 y week 12 in patients initially treated with intravenous corticosteroids included baseline total Mayo
74 nts, all of whom were initially treated with intravenous corticosteroids, underwent colectomy.
75 presenting with severe disease and requiring intravenous corticosteroids.
76 colectomy among those initially treated with intravenous corticosteroids.
77  141 with oral corticosteroids, and 143 with intravenous corticosteroids.
78                                          The intravenous crystalloid used in the unit alternated mont
79 h lymphodepleting conditioning chemotherapy (intravenous cyclophosphamide [60 mg/kg] daily for 2 days
80 notable and broadly consistent with previous intravenous delivery of other drugs and dyes with the hi
81            Collectively, these data validate intravenous delivery of rAAV2/9 as a novel and atraumati
82                               The controlled intravenous delivery of small-molecule Wnt agonists (Dkk
83  gemcitabine 675 mg/m(2) on days 1 and 8 and intravenous docetaxel 75 mg/m(2) on day 8 every 3 weeks.
84 n interactive web response system to receive intravenous docetaxel 75 mg/m(2) plus either intravenous
85 ts (6 PC, 2 BC, and 2 UBC) received a single intravenous dose of (68)Ga-NOTA-AE105 (154 +/- 59 MBq; r
86                          We infused a single intravenous dose of a codon-optimized adeno-associated v
87  mouse model of IP, we administered a single intravenous dose of the adeno-associated virus (AAV) vec
88 ndomly assigned 1:1 to receive six cycles of intravenous doxorubicin 75 mg/m(2) on day 1 every 3 week
89                                              Intravenous drug abuse (IVDA) is a known risk factor for
90                                              Intravenous drug use.
91 dministration of Nos (100 mg/kg) followed by intravenous DTX (5 mg/kg) liposome treatment revealed re
92 isorders have been an area of interest since intravenous enzyme replacement therapy was successfully
93  Whether correction of iron deficiency with (intravenous) ferric carboxymaltose (FCM) affects peak ox
94                                              Intravenous fluid administration up to the day of HUS di
95   The associations between hydration status, intravenous fluid administration, and outcomes of patien
96            Additional analyses incorporating intravenous fluid administration, including additional C
97  understand the effects of administration of intravenous fluid boluses and vasopressors in patients w
98 he secondary outcomes included the volume of intravenous fluid received and receipt of vasopressors.
99 target of 0.5 mL/kg/h and results in a large intravenous fluid sparing.
100 and to the completion of an initial bolus of intravenous fluid.
101              Exclusion criteria included: no intravenous fluids >/=48 hours, admission >/=14 days of
102                                     Clinical intravenous fluids (IVFs) of various tonicities are ofte
103  longer time to the completion of a bolus of intravenous fluids (odds ratio, 1.01 per hour; 95% CI, 0
104  3170 mL (95% confidence interval 2380-3960) intravenous fluids versus 5490 mL (95% confidence interv
105 esuscitation protocol with administration of intravenous fluids, vasopressors, and blood transfusion
106  not rapid completion of an initial bolus of intravenous fluids, were associated with lower risk-adju
107 e dose of 60 mg/m(2) on days 1 and 29), with intravenous fluorouracil (one dose of 1000 mg/m(2) per d
108 35 over 7 weeks) plus cisplatin at 100 mg/m2 intravenous for 3 doses (arm A) vs accelerated-fractiona
109 35 over 6 weeks) plus panitumumab at 9 mg/kg intravenous for 3 doses (arm B).
110 lone (USAN; formerly SAGE-547 injection), an intravenous formulation of allopregnanolone, a positive
111                                   We used an intravenous fractionated regimen of alpha-radioimmunothe
112 sistance (urine output </=125 ml/h following intravenous furosemide >/=40 mg).
113                             Infants received intravenous furosemide (1 mg/kg every 6 hours) or a stan
114 ts with intracranial abnormalities following intravenous gadolinium-based contrast agent (GBCA) expos
115 an primate tissue after maternal exposure to intravenous gadoteridol during pregnancy.
116 ents were randomized (1:1) to receive either intravenous ganciclovir (5 mg/kg twice daily for 5 days)
117  twice daily for 5 days), followed by either intravenous ganciclovir or oral valganciclovir once dail
118 ncluded 144 pediatric patients who underwent intravenous GBCA-enhanced MR imaging examinations (55 pa
119 ubicin 75 mg/m(2) on day 1 every 3 weeks, or intravenous gemcitabine 675 mg/m(2) on days 1 and 8 and
120                          Results showed that intravenous ghrelin, compared to placebo, significantly
121                     A 10-min loading dose of intravenous ghrelin/placebo (3 mcg kg(-1)) followed by a
122 rom the insulin-modified, frequently sampled intravenous glucose tolerance test (FSIGT), we estimated
123 = 389) had first-phase insulin release on an intravenous glucose tolerance test that was higher than
124                                              Intravenous glucose tolerance tests were performed befor
125 , which occurred in 44 patients (21%) in the intravenous group and 52 (26%) in the subcutaneous group
126 nduction was 84.9% (95% CI 79.2-89.5) in the intravenous group and 84.4% (78.7-89.1) in the subcutane
127 actions occurred in 73 patients (35%) in the intravenous group and 95 (48%) patients in the subcutane
128 ent failure was significantly higher for the intravenous group than the oral group [odds ratio (OR) 1
129 ilar in both groups (199 [95%] of 210 in the intravenous group vs 189 [96%] of 197 in the subcutaneou
130  catheter line complications was 3.2% in the intravenous group, and drug reactions were rare in both
131 ding the various topical, intracavitary, and intravenous hemostatic technologies in terms of material
132  changes following repeated subcutaneous and intravenous heroin challenges in mice and rats.
133 , multicenter study evaluated the effects of intravenous high-dose NAC (29 g over 2 days) with backgr
134  C1INH attenuated pulmonary damage evoked by intravenous histone instillation.
135 de administration of oral and, as necessary, intravenous hydration; systematic monitoring of vital si
136 e randomized 1:1 to treatment with serelaxin intravenous (i.v.) infusion (for 60 min at 80 mug/kg/d a
137 cavity, enabling elevated drug levels versus intravenous (i.v.) injection.
138 open-label study to determine whether 5 g of intravenous idarucizumab would be able to reverse the an
139                                              Intravenous illicit drug use (IDU) and hepatitis C infec
140 to 20% of patients do not respond to initial intravenous immune globulin, and recommendations for add
141 a mouse model of EV-D68 infection: (1) human intravenous immunoglobulin (hIVIG), (2) fluoxetine, and
142                                              Intravenous immunoglobulin (IVIG) are purified IgG prepa
143                                              Intravenous immunoglobulin (IVIG) is a FDA-approved drug
144                                              Intravenous immunoglobulin (IVIG) is sometimes administe
145                                              Intravenous immunoglobulin (IVIG), a pooled normal IgG f
146  and outcome of GBS in patients treated with intravenous immunoglobulin (IVIG).
147 nduced by injection of heat-aggregated human intravenous immunoglobulin and active systemic anaphylax
148                                              Intravenous immunoglobulin and corticosteroids were effe
149 or one immunosuppressive therapy and chronic intravenous immunoglobulin or plasma exchange for 12 mon
150 within 12 months before screening, or use of intravenous immunoglobulin or plasma exchange within 4 w
151 h definite or probable CIDP who responded to intravenous immunoglobulin treatment were eligible.
152 inating polyneuropathy (CIDP) need long-term intravenous immunoglobulin.
153 s among plasma donors, which is reflected in intravenous immunoglobulins (IVIGs).
154 rapy consisted of steroids (n = 61/74; 82%), intravenous immunoglobulins (n = 71/74; 96%), and plasma
155 phosphamide combined with plasmapheresis and intravenous immunoglobulins is an option for patients wi
156 d first-line immunotherapy with steroids and intravenous immunoglobulins vs. late immunotherapy), and
157 g therapies, including glucocorticosteroids, intravenous immunoglobulins, cyclosporine, plasmapheresi
158 from blood and several organs using a murine intravenous infection model.
159 e that in hamsters, pathology resulting from intravenous infection with adenoviruses is caused mostly
160 h titers in the liver of these animals after intravenous infection, while respiratory infection resul
161 s are trapped in the lungs immediately after intravenous infusion and their survival time in the host
162                  Avelumab was given as a 1-h intravenous infusion every 2 weeks.
163 n every 8 h) or 1000 mg meropenem (by 30-min intravenous infusion every 8 h) for 7-14 days; regimens
164  mg ceftazidime and 500 mg avibactam (by 2 h intravenous infusion every 8 h) or 1000 mg meropenem (by
165                         Patients received an intravenous infusion of 7.5 mg/kg MABp1 or placebo given
166 optimal medical treatment were randomized to intravenous infusion of allogenic UC-MSCs (Cellistem, Ce
167 lysis to compare prolonged versus short-term intravenous infusion of antipseudomonal beta-lactams in
168                                          The intravenous infusion of apolipoprotein E4 exacerbated th
169 m(2)] daily for 5 days, followed by a single intravenous infusion of autologous TILs and high-dose in
170  acute heart failure to receive a continuous intravenous infusion of either ularitide at a dose of 15
171 nderwent MRI at baseline then 24 h following intravenous infusion of ketamine (0.5 mg/kg).
172 oom temperature (22 degrees C) for 4 h or by intravenous infusion of the alpha-adrenergic receptor an
173      Evaluate the safety and efficacy of the intravenous infusion of UC-MSC in patients with chronic
174 56 mg/m(2) thereafter) was given as a 30-min intravenous infusion on days 1, 2, 8, 9, 15, and 16 of 2
175 m2 intravenous, and fluorouracil, 2400 mg/m2 intravenous infusion over 46-48 hours) on days 1 and 15
176  expression received avelumab (10 mg/kg, 1 h intravenous infusion) every 2 weeks until confirmed dise
177 ), whereas direct intramyocardial injection, intravenous infusion, and intracoronary infusion indicat
178 eceived gemcitabine 1000 mg/m(2) as a 30-min intravenous infusion, weekly, for 7 weeks followed by a
179  as did direct intramyocardial injection and intravenous infusion, whereas intracoronary infusion dem
180 etermined with the use of a [1-(13)C]leucine intravenous infusion.
181  administered in 28-day cycles by continuous intravenous infusion.
182 mit physiological insight, e.g. the need for intravenous infusions and restriction to short-term stud
183                                              Intravenous infusions of (13)C-labelled nutrients reveal
184 andomized equally to receive 15 double-blind intravenous infusions of adjunctive lanicemine 50 mg, la
185 ntuximab, 50 mg (week 1), followed by weekly intravenous infusions of girentuximab, 20 mg (weeks 2-24
186  receive ozanezumab (15 mg/kg) or placebo as intravenous infusions over 1 h every 2 weeks for 46 week
187 onger plasma circulation than free drug upon intravenous injection in mice.
188 nd mRNA encoding Cas9, we show that a single intravenous injection into mice induces >80% editing of
189                                  Single-dose intravenous injection of (131)I-CLR1404 significantly de
190           Patients received a single 150-MBq intravenous injection of (68)Ga-DOTATOC (15 mug of pepti
191 /CT images were acquired 60 +/- 10 min after intravenous injection of (68)Ga-PSMA (mean dose, 176 MBq
192 e effects were observed within 90 days after intravenous injection of 250 mg kg(-1) GS-AuNPs.
193 thelialium-specific activation of miR-195 by intravenous injection of aptamer-agomiR-195 stimulates C
194                                       Single intravenous injection of DC nanozymes (5kU of SOD1/kg) i
195                    Bacteremia was induced by intravenous injection of Escherichia coli Bacteremia cau
196            In vivo experiments revealed that intravenous injection of exosomes harvested after T/HS,
197 immunocompetent Sprague-Dawley rats received intravenous injection of ferumoxytol, and 18 Jax C57BL/6
198 the preclinical pig kidney transplant model, intravenous injection of GC7 before kidney removal signi
199                                              Intravenous injection of IL-33 or pulmonary fungal aller
200                                              Intravenous injection of Ms 9a-1 (0.3 mg/kg) produced a
201                            We also show that intravenous injection of singly encapsulated marrow stro
202                           However, following intravenous injection of tumor cells, mice lacking PITPa
203 retention of GC-PEG-PpIX were realized after intravenous injection, which ensured its effective imagi
204 lies on cell homing to the bone marrow after intravenous injection.
205 directly into the ossicle marrow space or by intravenous injection.
206 on scan, (11)C-nicotine was administered via intravenous injection.
207 TOC (15 mug of peptide) and 2 single 150-MBq intravenous injections of (68)Ga-OPS202 (15 mug of pepti
208           Patients received 2 single 150-MBq intravenous injections of (68)Ga-OPS202 3-4 wk apart (15
209 tee-approved study, healthy rats received 20 intravenous injections of 2.5 mmol gadolinium per kilogr
210  the last 3 weeks, a subset of rats received intravenous injections of lipopolysaccharide (LPS, 3 mg/
211 ce with oral ginsenoside Ro followed by HT29 intravenous inoculation and 40-day oral ginsenoside Ro s
212 nasal insulin application was mimicked by an intravenous insulin bolus on placebo day.
213 s similar in AAs and EAs after the 20-25 min intravenous insulin infusion.
214 ping renal toxicity due to administration of intravenous iodine- and gadolinium-based contrast materi
215 eived intravenous pembrolizumab 2 mg/kg plus intravenous ipilimumab 1 mg/kg every 3 weeks for four do
216 nous pembrolizumab every 3 weeks (n=277), or intravenous ipilimumab every 3 weeks (ipilimumab for fou
217 ); higher transferrin iron saturation index; intravenous iron use for anemia (adjusted odds ratio, 5.
218       Compared to free doxorubicin, a single intravenous (IV) administration of CP-Dox at the maximum
219 re determined following single oral (PO) and intravenous (IV) administration to cockatiels (Nymphicus
220 r cellular potency to be compatible with the intravenous (iv) dosing route required in AP.
221 el treatments, we have generated an improved intravenous (IV) formulation of HET0016 with HPssCD and
222 C01 administered either subcutaneously or by intravenous (IV) infusion and to assess the pharmacokine
223  safety and efficacy of 2 different doses of intravenous (IV) infusions of tocilizumab (TCZ), an IL-6
224  of the peptide into the CSF compared to the intravenous (IV) route, which requires blood-brain barri
225 h DSM-5 SAD and compared the effects between intravenous ketamine (0.5 mg/kg over 40 min) and placebo
226 the acute effect of adjunctive subanesthetic intravenous ketamine on clinically significant suicidal
227               In patients with bouts of OHE, intravenous LOLA (as an add-on therapy to lactulose and
228                 We evaluated the efficacy of intravenous LOLA in the reversal of bouts of OHE in pati
229 aintains prolonged voluntary abstinence from intravenous methamphetamine self-administration, to demo
230 n 54 of these participants, we also measured intravenous methylphenidate-induced dopamine release to
231 erate-to-severe ARDS onset to receive either intravenous midazolam or inhaled sevoflurane for 48 hour
232 patients (by minimisation) to receive either intravenous mitomycin (one dose of 12 mg/m(2) on day 1)
233 lgorithms and pointed to circumstances where intravenous monotherapy may be inadequate.
234                                              Intravenous MSCs eliminated the progressive deterioratio
235 placebo-controlled, dose-escalation trial of intravenous multipotent adult progenitor cells in 33 cen
236 D18 integrin-deficient (CD11b(-/-)) mice and intravenous myeloperoxidase infusion revealed that neutr
237                                    High-dose intravenous NAC administered with low-dose intravenous n
238                         We demonstrated that intravenous NAC administration promotes lysis of arteria
239 ent sample of smokers who participated in an intravenous nicotine infusion study that followed overni
240 e intravenous NAC administered with low-dose intravenous nitroglycerin is associated with reduced inf
241 ents and Methods Patients with mRCC received intravenous nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (N
242  carmustine plus 2 subsequent daily doses of intravenous O6-benzylguanine, administered every 2 weeks
243 multiple sclerosis in a 2:1 ratio to receive intravenous ocrelizumab (600 mg) or placebo every 24 wee
244 with relapsing multiple sclerosis to receive intravenous ocrelizumab at a dose of 600 mg every 24 wee
245 o assess the safety and clinical activity of intravenous ofatumumab monotherapy for untreated and rel
246  to evaluate the efficacy of the parenteral (intravenous or intramuscular) ondansetron vs traditional
247        Human immunoglobulin preparations for intravenous or subcutaneous administration are the corne
248                                     In mice, intravenous or sublingual administration of ICM led to a
249 GEN-5416/hypoxia-induced PAH rats than oral, intravenous, or intratracheal plain sildenafil did, when
250 arlisib (100 mg once daily) or placebo, plus intravenous paclitaxel (80 mg/m(2) on days 1, 8, 15, and
251 compare thoracic epidural analgesia (TEA) to intravenous patient-controlled analgesia (IV-PCA) for pa
252 patients were randomized to TEA (N = 106) or intravenous patient-controlled analgesia (N = 34).
253 kg every 3 weeks for four doses, followed by intravenous pembrolizumab 2 mg/kg every 3 weeks for up t
254                            Patients received intravenous pembrolizumab 2 mg/kg plus intravenous ipili
255 re enrolled and randomly assigned to receive intravenous pembrolizumab every 2 weeks (n=279), intrave
256 avenous pembrolizumab every 2 weeks (n=279), intravenous pembrolizumab every 3 weeks (n=277), or intr
257        All patients were treated with 200 mg intravenous pembrolizumab every 3 weeks.
258  and the absence of intraoperative lidocaine intravenous perfusion (odds ratio: 0.182, 95% CI 0.042-0
259                                              Intravenous Pi loading (0.5 mmol) caused a transient ris
260                       Conclusion Accelerated intravenous premedication with corticosteroids beginning
261 egnancy BMI >/=30) who had received standard intravenous preoperative cephalosporin prophylaxis.
262                                              Intravenous preparations have a number of important uses
263 ts The breakthrough reaction rate for 5-hour intravenous prophylaxis was 2.5% (five of 202 patients;
264 intravenous docetaxel 75 mg/m(2) plus either intravenous ramucirumab 10 mg/kg or matching placebo on
265 the case management of cholera with oral and intravenous rehydration therapy have reduced the case fa
266 ks, followed by combined therapy with 250 mg intravenous REP 2139 and 180 mug subcutaneous pegylated
267                     Patients received 500 mg intravenous REP 2139 once per week for 15 weeks, followe
268 non-inferiority of subcutaneous rituximab to intravenous rituximab in follicular lymphoma and to prov
269                                              Intravenous rituximab is the standard of care in B-cell
270 to 6-month therapy with NIAT and 375 mg/m(2) intravenous rituximab on days 1 and 8 (n=37) or NIAT alo
271 g capacity through either the enteral or the intravenous route is approximately 160 mumol/hour in con
272 als challenged with SHIVAD8-EO by mucosal or intravenous routes received a single 2-week course of tw
273                                              Intravenous rt-PA (recombinant tissue-type plasminogen a
274 s should evaluate the safety and efficacy of intravenous rt-PA in patients with ischemic stroke who a
275 7 patients with ischemic stroke treated with intravenous rt-PA within 4.5 hours, 251 were taking NOAC
276 he diagnosis was confirmed or excluded by an intravenous saline infusion test or captopril challenge
277 d responding for and intake of cocaine in an intravenous self-administration test.
278 actice of treating PAH patients with oral or intravenous sildenafil suffers from the limitations of s
279                                              Intravenous, single-dose administration of fibrinogen co
280                                              Intravenous sodium bicarbonate and oral acetylcysteine a
281                                              Intravenous thrombolysis (IVT) followed by mechanical th
282             However, it is not known whether intravenous thrombolysis (IVT) is of added benefit in pa
283 y performance indicator for efficient use of intravenous thrombolysis in acute ischemic stroke (AIS).
284                                              Intravenous thrombolysis with tissue-type plasminogen ac
285                   Six patients (4%) received intravenous tissue plasminogen activator without complic
286  for all transferred patients suggested that intravenous tissue plasminogen activator would be delaye
287 ae, and the possibility to offer patients an intravenous-to-oral switch therapy was supported by the
288 te ischaemic stroke patients with or without intravenous tPA treatment, compared to 115 age and gende
289 1 ischemic stroke patients were treated with intravenous tPA within 4.5 hours of symptom onset from 8
290          However, there is an unmet need for intravenous treatment for patients admitted to hospital
291                                              Intravenous treatment of mice with adenosine or agonists
292  interactive voice or web system, to receive intravenous tremelimumab (10 mg/kg) or placebo every 4 w
293                                              Intravenous urography, voiding cysto-urethrography and M
294       Ultrasound examination was followed by intravenous urography, voiding cysto-urethrography and M
295 te heart failure, early intervention with an intravenous vasodilator has been proposed as a therapeut
296  900 mg per day according to weight, oral or intravenous) versus identical placebo, together with sta
297 nts were randomly assigned to receive 300 mg intravenous zanamivir (n=201), 600 mg intravenous zanami
298 300 mg intravenous zanamivir (n=201), 600 mg intravenous zanamivir (n=209), or 75 mg oral oseltamivir
299  95% CI -1.79 to 0.75; p=0.25) in the 300 mg intravenous zanamivir group and 5.63 days (difference of
300 clinical response of 5.14 days in the 600 mg intravenous zanamivir group, the median time to clinical
301 ays or 5-6 days) to receive 300 mg or 600 mg intravenous zanamivir, or standard-of-care (75 mg oral o

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top